Skip to main content
TipRanks
Go Ultimate75% OFF

Hua Medicine (HUMDF) AI Stock Analysis

1 Followers
HUMDF

Hua Medicine

(Other OTC:HUMDF)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Revenue GrowthRapid 2025 revenue expansion indicates stronger commercial traction for dorzagliatin and growing demand in the company’s diabetes franchise. If maintained, this top-line momentum can broaden market penetration, improve operating leverage, and support greater reinvestment in the product pipeline.
Negative Factors
Negative Cash GenerationNegative operating and free cash flow show that reported business performance is not currently translating into internally generated funding. Persistent cash burn could require greater use of financial resources or external funding, reducing flexibility to expand commercialization and advance pipeline programs.

Hua Medicine (HUMDF) vs. SPDR S&P 500 ETF (SPY)

-60%-40%-20%0%20%HUMDF-52.08%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$303.18M
Dividend Yield
―
Average Volume (3M)
2,000
Price to Earnings (P/E)
-18.1
Beta (1Y)
0.10
Revenue Growth
82.93%
EPS Growth
-110.17%
Country
US
Employees
424
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Hua Medicine Business Overview & Revenue Model

Company Description

Hua Medicine (Shanghai) Ltd., a biopharmaceutical enterprise established in 2011 and headquartered in Beijing, China, specializes in the clinical development of novel therapeutic solutions, with a primary focus on addressing diabetes within the Chine...

Hua Medicine Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

HUMDF against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HK:3320HK:332079OutperformHKD 27.61B5.867.92%5.45%7.94%52.83%
HK:3692HK:369275OutperformHKD 208.73B26.5918.26%1.41%24.97%43.23%
HK:0013HK:001373OutperformHKD 20.31B160.391.43%―-8.55%-96.20%
HK:1513HK:151369NeutralHKD 29.40B18.1011.32%6.22%-9.56%-23.22%
HK:9989HK:998956NeutralHKD 14.23B69.681.58%4.14%-1.32%-50.00%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-40%-20%0%20%HUMDFHK:0013HK:1513HK:3320HK:9989HK:3692Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
HUMDF and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
HUMDFHua Medicine 0.28-0.30-52.08%
HK:0013HUTCHMED (China) Limited23.28-0.02-0.09%
HK:1513Livzon Pharmaceutical Group Class H25.00-3.31-11.69%
HK:3320China Resources Pharmaceutical Group Ltd.4.39-0.29-6.19%
HK:9989Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H4.01-1.34-24.97%
HK:3692Hansoh Pharmaceutical Group Company Limited34.42-4.40-11.33%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.